Hanger Inc

Hanger — Investor Presentation (August 2012)

29 slides from Hanger's investor presentation, Aug 6, 2012

  1. Slide 1: Investor Presentation: 150 Years of Empowering Human Potential

    150 YEARS Investor Presentation of Empowering Human Potential. August 2012

  2. Slide 2: Safe Harbor

    SAFE HARBOR Except for the historical information contained herein, the matters discussed in this presentation constitute forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those projected. These include the rate at which Hanger

  3. Slide 3: Vision

    VISION Be the partner of choice for products and services that enhance human physical capability. 2

  4. Slide 4: Overview

    OVERVIEW 3 $953 million in revenues LTM Adjusted EBITDA $155 million LTM

  5. Slide 5: Overview

    OVERVIEW 4 DISTRIBUTION 11% of revenues $105 million revenue THERAPEUTIC SOLUTIONS 7 % of revenues $63 million revenue ACP, Inc. IN, Inc. PATIENT CARE 82 % of revenues LTM $785 million revenue LTM Linkia $953 million in revenues LTM Adjusted EBITDA $155 million LTM

  6. Slide 6: Overview

    OVERVIEW 5 $953 million in revenues LTM Adjusted EBITDA $155 million LTM THERAPEUTIC SOLUTIONS 7 % of revenues $63 million revenue ACP, Inc. IN, Inc. DISTRIBUTION 11% of revenues $105 million revenue PATIENT CARE 82 % of revenues LTM $785 million revenue LTM Linkia

  7. Slide 7: Overview

    OVERVIEW 6 $953 million in revenues LTM Adjusted EBITDA $155 million LTM THERAPEUTIC SOLUTIONS 7 % of revenues $63 million revenue ACP, Inc. IN, Inc. DISTRIBUTION 11% of revenues $105 million revenue PATIENT CARE 82 % of revenues LTM $785 million revenue LTM Linkia

  8. Slide 8: Disciplined Diversification of Revenue

    DISCIPLINED DIVERSIFICATION OF REVENUE 7 $4.6 Billion Addressable Market 29% 10%

  9. Slide 9: Compelling Growth Drivers

    COMPELLING GROWTH DRIVERS 8 Sources: Company estimates; Wall Street Research; 2003–2006 National Health and Nutrition Examination Survey; National Institutes of Health; Amputee Coalition of America. Aging Population (U.S.) (%) Diabetes – Prevalence By Age Group Disease and aging population Advancing

  10. Slide 10: Patient Care

    PATIENT CARE 9

  11. Slide 11: Profile: Patient Care

    10 PROFILE PATIENT CARE One or more certified clinicians Technical personnel Office administrators Line of site incentives to grow revenues and collect receivables CAGR up 6.7% (2008–2011) Business Overview Center Overview Over 700 O&P patient-care centers Over 1,195 O&P certified and licensed clini

  12. Slide 12: Market Position: Patient Care

    11 MARKET POSITION PATIENT CARE Only national or regional provider Hanger operates ~25% of accredited O&P facilities No other provider has more than 2% market share Adjacent market of $1.4 Billion Principal Reimbursement Sources for Patient Care Services $2.6 Billion US Market

  13. Slide 13: Patient Care Growth Opportunities

    PATIENT CARE First to market with new technologies and products Linkia Network Management Diversification into new adjacent businesses CARES Dosteon Solutions Small O&P acquisitions Sales synergies with ACP 12 GROWTH OPPORTUNITIES

  14. Slide 14: Linkia Network Management

    LINKIA First and only O&P network management company Insurers’ exclusive or preferred provider of their network Hanger network of approximately 1,050 O&P centers 53 contracts; 1–3 years; auto renew Value proposition to large name companies through expanded services 28% CAGR of contracted revenues (2

  15. Slide 15: Distribution

    DISTRIBUTION 14

  16. Slide 16: Distribution Profile

    DISTRIBUTION Largest dedicated distributor of O&P devices and components Over 29,000 O&P related items 6 strategically located distribution facilities Comprehensive Customer Service Manufacture and distribute therapeutic footwear Net sales $105 million LTM and CAGR of 7.6% (2008–2011) Inter-company

  17. Slide 17: Distribution Opportunities

    DISTRIBUTION Increase depth and breadth of product line Increase penetration of existing customer base Expand customer base Expand market presence geographically Apply core competencies to adjacent businesses Expand O&P fabrication operation to Independent O&P Providers 16 OPPORTUNITIES

  18. Slide 18: Therapeutic Solutions

    THERAPEUTIC SOLUTIONS 17

  19. Slide 19: Therapeutic Solutions: Diversification of Revenue

    THERAPEUTIC SOLUTIONS Innovative Neurotronics Development and commercialization of products V-Hold and WalkAid Accelerated Care Plus (ACP) Value proposition to rehabilitation providers Technology, clinical modalities, training and education 18 DIVERSIFICATION OF REVENUE

  20. Slide 20: ACP Overview

    ACP OVERVIEW 19 ACP enables post-acute providers with 24 evidence-based clinical therapy programs Physical Agent Modality Basics Wound Healing Fall Prevention Continence Improvement Contracture Management Pain Management Physical Agent Modality Basics Osteoarthritis of the Knee Orthotic Therapy Hemi

  21. Slide 21: Financial Overview

    FINANCIAL OVERVIEW 20

  22. Slide 22: Solid Financial Position

    SOLID FINANCIAL POSITION Earnings and margin growth Substantial cash flow generation Strong balance sheet management Moderate leverage post ACP acquisition Consistent reduction of leverage 21

  23. Slide 23: Q2 2012 in Review

    Q2 2012 IN REVIEW Same Store Sales 4.6% 8.9% growth in Adjusted EBITDA 11.1% increase in earnings per share Leverage ratio to 2.88X Total liquidity at 6/30/2012 was $141.1 Million including $41.6 of cash Total Debt $504.4 Million 22

  24. Slide 24: Revenue Growth

    REVENUE GROWTH 23 ($ in millions)

  25. Slide 25: Adjusted EBITDA Growth and Margins

    ADJUSTED EBITDA GROWTH AND MARGINS* 24 CAGR 16.4% Excludes relocation expenses and cost related to acquisitions. Adjusted EBITDA Adjusted EBITDA Margins % ($ in millions)

  26. Slide 26: Growth in Adjusted EPS

    GROWTH IN ADJUSTED EPS* 25 * Excludes relocation expenses, cost related acquisitions and the accelerated non-cash preferred dividend in 2008. ($ in millions)

  27. Slide 27: Steady Comparable Quarter Growth

    STEADY COMPARABLE QUARTER GROWTH 26 2010 2011 2012 Adjusted EBITDA* ($ in millions) * Excludes relocation expenses and cost related to the ACP acquisition. Revenues ($ in millions) Adjusted Earnings Per Diluted Share* * Excludes relocation expenses, cost related to the ACP acquisition and accelerate

  28. Slide 28: Key Investment Points

    KEY INVESTMENT POINTS Compelling industry growth drivers Dominant market position Attractive organic growth opportunities Adjacent continuum of care opportunities Proven acquisition capabilities Solid financial position 27

  29. Slide 29: Hanger: Empowering Human Potential

    ~* Hanger -* Hanger Empowering Human Potential (NYSE: HGR) * Hanger CLINIC Empowering Hur BD» POSTEON LINKIA CAS >SPS INNOVATIVE NEUROTRONICS

Hanger — Investor Presentation (August 2012) on 6ix